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Zinc	 ribbon	domain	containing	1	 (ZNRD1)	gene	
encoding	a	protein	consisting	of	two	zinc	ribbon	do‑
mains	was	cloned	from	the	human	HLA� locus in 2000	 	 	 	
[1].	The	zinc	 ribbon	domain	was	a	ubiquitous	motif	
in	archaeal	and	eucaryotic	transcription	factors,	and	
has	been	proved	to	be	a	functional	domain	required	
for	biological	activities	in	TFIIS	and	TFIIB	[2–4].	The	
zinc	ribbon	domain	at	the	C‑terminal	of	ZNRD1	protein	
(Cx2Cx24Cx2C)	was	actually	folded	as	three	ß‑sheets	
stabilized	by	a	zinc	ion	instead	of	finger‑like	helices,	
forming	a	zinc	ribbon	structure	fitting	TFIIS	zinc	ribbon	
fold	(C‑terminal	residues	231–281)	very	well	[5].	A�nd	
the	analogous	Cys4	structural motifs were well con‑	 	 	 	
served	throughout	evolution,	including	archaea,	yeast,	
drosophila,	nematodes,	amphibians,	and	mammals,	
and	might	play	important	roles	in	promoting	cleavage	
of	 the	nascent	transcript	and	read‑through	past	 the	
block	to	elongation	[6,	7].	Recently,	ZNRD1	has	been	
found	related	to	multidrug	resistance	(MDR),	tumori‑
genesis	and	cell	cycle.	Taken	together,	ZNRD1	might	
be	associated	with	transcription	regulation	and	might	
play	potential	roles	 in	mediating	some	physiological	
and	pathological	functions.
EffEcts of ZNRD1 oN multiDRug 
REsistaNcE
Multidrug	resistance	(MDR)	is	a	major	impediment	
to	the	effective	chemotherapy	of	many	human	malig‑
nancies.	Molecular	investigations	discovered	diverse	
mechanisms	of	MDR,	such	as	extrusion	of	the	drug	by	
cell	membrane	pumps	including	P‑glycoprotein	(P‑gp)	
and	multidrug	resistance‑associated	protein	(MRP),	
enhanced	drug	detoxification,	increased	DNA�	damage	
repair,	 redistribution	of	 intracellular	accumulation	of	
drugs,	modification	of	drug	target	molecules,	suppres‑
sion	of	drug‑induced	apoptosis,	up‑regulation	of	lipids	
and	other	biochemical	alterations	 [8–12].	Recently,	
ZNRD1	was	found	to	play	important	roles	in	MDR	of	
gastric	cancer	and	leukemia.
ZNRD1	was	foundover‑expressed in the vincristine	 	 	 	 	
(VCR)‑resistant	gastric	cancer	cell	line	SGC7901/VCR	
and	the	VCR‑resistant	leukemia	cell	line	HL‑60/VCR,	
compared	with	 their	 corresponding	 parental	 cell	
lines	SGC7901 and HL‑60, respectively [13, 14]. To	 	 	 	 	 	 	
detect	the	role	of	ZNRD1	in	MDR	of	tumor	cells,	the	
recombinant	 plasmids	 containing	 the	 full	ORF	of	
wild‑type ZNRD1 and the siRNA� vectors of ZNRD1	 	 	 	 	 	 	 	
were	constructed.	Using	these	vectors,	the	cell	models	
with	elevated	or	decreased	ZNRD1	expression	were	
established. MTT assay revealed that ZNRD1 had	 	 	 	 	 	 	
different	effects	on	drug	sensitivity,	depending	on	the	
drug	used.	The	 tumor	cells	overexpressing	ZNRD1	
showed	a	>	12‑fold	increased	resistance	to	VCR	and	
adriamycin	 (A�DR),	and	a	>	5‑fold	 increased	 resis‑
tance	to	5‑fluorouracil	(5‑FU)	and	cisplatin	(CDDP)	as	
compared	with	control	cells	(P <	0.01)	[15].	A�nd	the	
cells	with	decreased	ZNRD1	expression	showed	sig‑
nificantly	increased	sensitivity	to	A�DR,	VCR	(>	4‑fold),	
and	5‑FU,	CDDP	(>	2‑fold)	[16].
A�DR	was	used	as	probe	to	evaluate	drug	accumu‑
lation	and	retention	in	the	cell	models.	A�s	the	reports	
showed,	up‑regulation	of	ZNRD1	was	accompanied	
with	significantly	decreased	A�DR	accumulation	and	re‑
tention	and	increased	A�DR	releasing	index.	Consistent	
with	this,	down‑regulation	of	ZNRD1	led	to	increased	
A�DR	accumulation	and	retention	and	decreased	A�DR	
releasing	 index.	The	 results	 indicated	 that	ZNRD1	
had	a	direct	or	indirect	function	of	pumping	drug	out	
of	cells	[14],	which	might	result	from	ZNRD1‑induced	
up‑regulation	of	P‑gp.	A�nd	 the	P‑gp	 inhibitor,	vera‑
pamil,	could	partially	 reverse	 the	effects	of	ZNRD1	
on	 drug	 sensitivity	 in	 gastric	 cancer	 or	 leukemia	
cells,	especially	 for	VCR	and	A�DR,	suggesting	 that	
regulation	of	P‑gp	might	be	one	of	the	mechanisms	
by	which	ZNRD1	mediated	MDR	[16].	Each	case	of	
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P‑gp‑related	MDR	has	been	related	to	an	increased	
human	multidrug	 resistance	gene	1	 (MDR1)	mRNA�	
level	 that	can	be	 linked	either	 to	gene	amplification	
and/or	increased	gene	transcription	[17].	It	is	believed	
that	alterations	in	MDR1	promoter	are	 important	for	
P‑gp	 function	 [18].	Co‑transfection	of	cancer	cells	
with	MDR1	reporter	gene	and	increasing	amounts	of	
ZNRD1	expression	vectors	resulted	in	a	linear	increase	
in	MDR1	promoter	activity,	 suggesting	 that	ZNRD1	
might	be	a	transcriptional	regulator	of	the	MDR1	gene.	
The	results	of	reporter	gene	assay	revealed	that	puta‑
tive	ZNRD1	binding	sites	are	located	among	–136–+10	
in	 the	MDR‑1	promoter	 [14,	16].	However,	 the	 role	
of	ZNRD1	might	depend	not	only	on	 the	promoter	
sequences	but	also	on	the	association	of	ZNRD1	with	
different	cofactors.	The	precise	mechanism	by	which	
ZNRD1	influences	MDR1	gene	expression	is	the	sub‑
ject	of	future	experimental	work.
It	should	be	noted	that	VCR	and	A�DR	are	the	com‑
mon	substrates	for	P‑gp.	But	the	ZNRD1‑related	re‑
sistance	to	5‑FU	and	CDDP	couldn’t	be	explained	by	
regulation	of	P‑gp,	which	suggested	that	other	mecha‑
nisms	might	exist.	However,	glutathione‑S‑transfe‑
rase	 (GST)‑mediated	drug‑detoxifying	system	and	
MRP	was	not	 found	 to	be	 significantly	 involved	 in	
ZNRD1‑mediated	MDR	[14].	Recently,	it	was	proposed	
that	ZNRD1	might	mediate	the	MDR	through	regula‑
tion	of	apoptosis	[19].
A�poptosis	is	a	common	pathway	that	finally	medi‑
ated	the	killing	functions	of	anticancer	drugs.	The	gas‑
tric	cancer	cells	overexpressing	ZNRD1	displayed	an	
impaired	capacity	to	undergo	A�DR‑induced	apoptosis,	
whereas	control	cells	displayed	a	higher	proportion	
of	cells	undergoing	apoptosis	after	A�DR	 treatment	
[19].	Bcl‑2	family,	 including	Bcl‑2,	Bcl‑xL,	Bax,	Bad	
and	Bak,	 is	 a	 rapidly	expanding	 family	of	proteins	
involved	 in	apoptosis	and	 responses	of	 tumor	cells	
to	chemotherapy	[20].	These	proteins	were	believed	
to	modulate	apoptosis	by	 forming	homodimers	or	
heterodimers	with	other	Bcl‑2	family	members	[21].	
A�	wide	variety	of	human	cancers,	with	poor	clinical	
response	 to	chemotherapy,	exhibited	high	 levels	of	
bcl‑2	expression.	It	had	been	implied	that	bcl‑2	fami‑
ly	expression	provided	resistance	to	a	wide	variety	of	
cell	 death	stimuli,	 including	classical	 chemothera‑
peutic	drugs	and	radiation	[22].	The	changed	levels	
of	Bcl‑2	caused	by	ZNRD1	might	also	contribute	to	
suppression	effects	of	ZNRD1	on	apoptosis	and	thus	
ZNRD1‑related	MDR	of	gastric	cancer	cells.
A�nother	molecule	regulated	by	ZNRD1	is	inosine	
monophosphate	dehydrogenase	2	(IMPDH2),	which	
catalyzes	 the	 last	 step	 in	 the	 synthesis	of	 inosine	
monophosphate.	The	chemical	 inhibitors	of	 IMPDH	
activity	are	already	used	in	cancer	therapy,	suggesting	
the	possibility	to	use	them	as	modulators	in	combina‑
tion	with	methotrexate	(MTX),	which	is	an	inhibitor	of	
dihydrofolate	reductase	(DHFR),	an	enzyme	involved	
in	nucleotide	synthesis	[23].	Decreased	IMPDH2	was	
found	 responsible	 for	 the	ZNRD1‑mediated	 tumor	
resistance	 to	MTX	 in vitro.	 In vitro	 drug	 sensitivity	
analyses	also	revealed	that	down‑regulationof ZNRD1	 	 	
expression	might	decrease	 the	capacity	of	cells	 to	
resist	to	MTX by inhibiting IMPDH2 [19].	 	 	 	
Taken	together,	ZNRD1	might play certain roles in	 	 	 	 	
MDR	through	P‑gp	signal	pathway	and/or	coopera‑
tion	with	Bcl‑2	and	IMPDH2.	Further analysis for the	 	 	 	
mechanism	of	biological	actions	of	ZNRD1	 in	MDR	
might	help	to	further	understand	the	mechanisms	of	
MDR	and	generate	a	new	approach	to	reverse	MDR.
EffEcts of ZNRD1  
oN tumoRigENEsis
Our	 laboratory	 has	 a	 long‑standing	 interest	 in	
the	possible	role	of	ZNRD1.	We	have	generated	the	
first	mouse	monoclonal	antibody	(clone	H6)	specific	
for	ZNRD1	protein.	With	this	monoclonal	antibody	in	
Western	blotting,	ZNRD1	was	found	to	be	down‑regu‑
lated	in	16	cases	of	human	gastric	cancer	tissues	as	
compared	 to	 the	matched	adjacent	nonneoplastic	
tissues	(P <	0.001)	[24].	A�lso,	ZNRD1	expression	was	
found	to	be	down‑regulated	in	gastric	cancer	cell	lines	
(A�GS,	MKN28,	MGC803,	SGC7901)	compared	with	
normal	gastric	epithelial	cell	 line	(GES)	[25].	 Immu‑
nohistochemical	analysis	revealed	that	normal	gastric	
epithelium	cells	might	have	a	constitutive	basal	level	
of	ZNRD1	expression	for	mediating	the	normal	physio‑
logic	functions.	ZNRD1	staining	was	found	positive	in	
38	(63%)	normal	epithelia	samples,	51	(81%)	gastritis	
samples,	and	7	(8%)	adenocarcinoma	cases.	The	ex‑
pression	of	ZNRD1	in	nontransformed	gastric	tissues	
was	significantly	(P <	0.001)	higher	than	that	in	tumor	
tissues	[26].	Statistical	analysis	showed	that	there	was	
no	significant	correlation	between	the	expression	of	
ZNRD1	and	the	differentiation,	metastasis	and	Dukes’	
stage	of	gastric	carcinoma,	sex,	age,	or	nationality	of	
patients.
ZNRD1	expression	 in	normal	gastric	epithelium	
may	be	up‑regulated	 in	 response	 to	various	stimuli	
such	as	 injury	or	alteration	of	 the	environment;	 for	
example,	upon	gastritis,	expression	 level	of	ZNRD1	
was	increased	with	a	statistically	significant	difference	
(P <	0.001).	The	patterns	of	ZNRD1	expression,	fre‑
quently	absent	in	gastric	cancer	tissues	(86/93	(92%)),	
were	 typical	 for	 tumor	 suppressor	genes	 [26].	We	
are	now	performing	 the	experiments	 to	 investigate	
whether	 ZNRD1	 is	 related	 to	DNA�	damage	 repair	
system,	or	whether	 it	carries	 the	possible	promoter	
methylation	and	mutation.	So,	ZNRD1	may	be	an	
ideal	marker	of	gastric	 cancer	and	could	be	used	
for	a	screening	purpose.
The	 involvement	of	 specific	genes	 in	 tumorige‑
nesis	could	be	confirmed	by	reconstituting	cells	null	
by	activity	with	 the	 respective	gene.	ZNRD1	cDNA�	
was	transfected	into	A�GS	gastric	cancer	cells,	which	
was	ZNRD1	null,	 and	 three	clones	overexpressing	
ZNRD1	were	 identified.	Up‑regulation	 of	 ZNRD1	
has	been	shown	 to	 inhibit	 the	growth	of	A�GS	cells	
in vitro	and	possess	anti‑carcinogenic	activity	in vivo	
[25].	What’s	more,	the growth inhibitory rate of A�GS	 	 	 	 	 	
transfectants	depended	on	 the	expression	 levels	of	
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ZNRD1.	Down‑regulation of ZNRD1 in normal gastric	 	 	 	 	 	
epithelium	cell	 line	GES	with	siRNA�	of	ZNRD1	could	
enhance	cell	growth	significantly	and	promoted	cells	
transition	 from	G1	phase	 to	S	phase.	However, the	 	
cell	proliferation	of	gastric	cancer	cell	line	SGC7901,	
which	normally	expresses	ZNRD1,	was	hardly	affected	
by	up‑regulation	of	ZNRD1,	supporting	the	idea	that	
inactivation	of	ZNRD1	might	be	only	one	of	the	routes	
of	gastric	tumorigenesis [25].	
So	far,	the	report	about	the	role	of	ZNRD1	in	tumori‑
genesis	 is	 focused	on	gastric	cancer.	These	results	
have	indicated	that	ZNRD1	possessses	growth	sup‑
pressor	activity	in	gastric	cancer	cells,	suggesting	that	
ZNRD1	may	play	important	roles	in	carcinogenesis	of	
gastric	cancer	through	transcription	regulation.	Thus,	
ZNRD1	might	be	a	novel	negative	modifier	in	gastric	
carcinogenesis.
EffEcts of ZNRD1  
oN cEll cyclE
It	was	currently	believed	that	the	loss	of	normal	cell	
cycle	control	played	an	important	role	 in	the	genesis	
of	most,	if	not	all,	tumors.	Cell	cycle	progression	was	
governed	by	the	actions	of	regulators	in	the	eukaryotic	
cell,	including	cyclins	and	CDKs	as	positive	regulators,	
whereas	CKIs	served	as	negative	 regulators	 [27].	 In	
normal	cells,	the	proliferation	is	under	strict	regulation	
and	these	regulators	work	in	concert	to	ensure	a	regu‑
lated	transition	from	one	phase	of	the	cell	cycle	to	the	
next.	In	tumor	cells,	this	exquisite	balance	between	the	
positive	and	negative	regulators	is	not	maintained,	thus	
contributing	to	the	malignant	phenotype.	Therefore,	the	
cell	cycle	regulatory	proteins	have	been	under	intense	
investigation	as	the	potential	molecular	targets.
ZNRD1	was	found	to	induce	the	arrest	of	A�GS	cells	
and	the	fibroblast	cell	line	NIH3T3	at	the	G1	phase	of	
the	cell	cycle	as	a	consequence	of	inhibition	of	cyclin	
D1	expression	[25,	26].	Thus,	ZNRD1	was	assumed	
to	play	 important	 roles	 in	G1	checkpoint.	Passage	
through	 the	G1	 checkpoint,	 called	the	 restriction	
point,	allowed	cells	to	progress	through	the	cell	cycle	
in	an	autonomous	and	mitogen‑independent	man‑
ner.	Cyclins	belonging	 to	 the	D	and	E	 families,	and	
their	respective	kinase	partners,	CDK4/6	and	CDK2,	
were	involved	in	G1	restriction	point	control	[28]. Cy‑
clin D1/CDK4	complexes	governed	G1	progression,	
whereas	cyclin	E/CDK2	complexes	controlled	entry	
into	S	phase. Cyclins	were	regulated	not	only	at	 the	
transcriptional	and	translational	levels	but	also	by	their	
rate	of	degradation	via	the	ubiquitin	pathway	[29].	A�n	
additional	level	of	negative	control	was	produced	by	
the	expression	of	CDK	inhibitors,	including	KIPs	(p21,	
p27, p57) and INKs (p15, p16, p18, p19) [30, 31].	 	 	 	 	 	 	 	 	
A�s	indicated	by	the	results	of	microarray,	up‑regula‑
tion	of	ZNRD1	led	to	decreased	CDK4,	increased	p21,	
p27 and the retinoblastoma gene (pRB), all of which	 	 	 	 	 	 	 	 	
were	proved	to	play	important	roles	in	regulating	the	G1	
to	S	transition	[19].	Cyclin	D1	was	known	to	play	at	least	
two	important	roles	in	facilitating	the	transition	from	G1	
phase	into	S.	First,	it	served	as	the	regulatory	subunit	of	
CDK4	and	contributed	to	its	stability,	allowing	the	initial	
phosphorylation	of	pRb	in	mid‑G1.	Second,	it	acted	in	
complex	with	its	partner	kinase	to	sequester	the	cip/kip	
kinase	inhibitors. The	effects	of	ZNRD1‑induced	re‑
duction	of	cyclin	D1	could	be	reasonably	linked	to	the	
mechanisms	of	the	cell	cycle	arrest	both	through	the	
resulting	inability	of	unbound	CDK4	to	phosphorylate	
pRb	and	through	the	potential	decrease	in	the	asso‑
ciation	of	cyclin	D/CDK4	complexes	with	p21	and/or	
p27.	With	limited	sequestration	of	the	cip/kip	proteins,	
increased	levels	of	p27 and/or p21 would be free to	 	 	 	 	 	 	
associate	with,	and	hence	decreased	 the	ability	of,	
cyclin	E/CDK2	complexes.	The	ZNRD1‑induced	 in‑
creased	expression	of	hypo‑phosphorylated	form	of	
pRb	might	also	exert	a	growth	suppressive	effect	by	
indirectly	influencing	transcription	of	cell‑cycle	related	
genes	through	sequestration	of	critical	transcription	
factors,	such	as	E2F.
coNclusioNs aND futuRE 
pERspEctivEs
ZNRD1	 is	down‑regulated	 in	gastric	cancer,	and	
could	suppress	the	growth	of	gastric	cancer	cells	by	cell	
cycle	arrest	in	G1	phase	mediated	by	down‑regulation	
of	 cyclin	D1.	Meanwhile,	ZNRD1	might	be	 related	
to	MDR	of	gastric	cancer	and	 leukaemia	by	 regula‑
tion	of	P‑gp,	Bcl‑2,	and	IMPDH2.	It	is	interesting	that	
ZNRD1	gene	expression	could	not	only	enhance	the	
proliferative	activity	of	gastric	cancer	cells	after	che‑
mothearpeutic	drugs	treatment,	but	also	suppresses	
the	 tumorigenesis	activity	of	gastric	cancer	cells	 in	
animals.	These	results	seemed	controversy	and	brought	
some	philosophical	thinks.	There might be a balance.	 	 	 	 	
A�s	shown	 in	Fig.	1,	ZNRD1 was down‑regulated in	 	 	 	
gastric	cancer	cells,	where	it	was	under	the	balance,	
so	up‑regulation	of	ZNRD1	could	reverse	the	mailgnant	
phenotype	of	tumor	cells.	ZNRD1	was	highly	expressed	
in	gastric	cancer	MDR	sublines,	where	it	was	above	the	
balance,	so	we	have	to	down‑regulate	ZNRD1	expres‑
sion	so	as	to	reverse	the	MDR	phenotype	of	tumor	cells.	
Similar	balance	might	also	work	for	other	molecules,	
for	example,	DA�RPP‑32	was	 found	highly	expressed	
in	gastric	cancer	but	down‑regulated	in	gastric	cancer	
MDR	sublines	[32].
ZNRD1 Transcription P-gp, Bcl-2,  IMPDH2
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fig. 1. Functionsof ZNRD1. ZNRD1 is down‑regulated in gastric	 	 	 	 	 	 	 	
cancer,	up‑regulation	of	ZNRD1	could	 reverse	 the	malignant	
phenotype	of	tumor	cells.	ZNRD1	is	highly	expressed	in	gastric	
cancer	MDR	sublines,	so	down‑regulation	of	ZNRD1	could	re‑
verse	the	MDR	phenotype	of	tumor	cells
It	 is	 interesting	 that	ZNRD1	seems	 to	be	 related	
to	DNA�	damage	repair	as	 following:	 firstly,	ZNRD1	 is	
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a	 transcription‑associated	 factor,	while	a	number	of	
investigations	had	shown	 that	 transcription	factors,	
such	p53,	c‑Myc,	and	A�P‑1	(c‑jun	and	c‑fos)	[33],	are	
involved	 in	 the	 regulation	of	stress‑inducible	genes.	
A�ctivation	of	transcription	factors	by	DNA�	damage	would	
directly	enhance	the	transcription	of	their	downstream	
genes,	which	might	exert	biological	functions	in	cellular	
response.	Secondly,	ZNRD1	is	found	up‑regulated	in	
response	to	treatment	with	DNA�	damaging	agents	(che‑
motherapeutic	drugs),	and	the	expression	of	ZNRD1	is	
significantly	higher	in	gastric	tissues	than	in	normal	gas‑
tric	epithelial	tissues	and	gastric	cancer	tissues.	Lastly,	
ZNRD1	might	be	a	cell	growth	arresting	factor,	which	is	
commonly	induced	in	response	to	DNA�	damage	in	both	
bacteria	and	eukaryotes	[34].	Taken	together,	it	could	
be	assumed	that	after	DNA�	damage,	ZNRD1	would	be	
able	to	 regulate	cell	cycle	progression	and	delicately	
coordinate	with	some	other	gene	regulators	to	ensure	
the	establishment	of	cellular	defense	network.	However,	
further	studies	are	required	 to	 investigate	 the	role	of	
ZNRD1	in	the	DNA�	damage‑activated	response.
It	was	becoming	increasingly	clear	that	the	signals	
that	govern	cellular	processes,	such	as	entry	and	exit	
from	 the	cell	cycle,	MDR,	and	DNA�	damage	 repair,	
function	in	complex	regulatory	networks	rather	than	
simple	linear	pathways,	and	that	these	networks	might	
be	wired	differently	in	different	cells	or	tumor	types.	A�s	
shown	in	Fig.	2,	ZNRD1	is	found	to	play	roles	in	MDR,	
tumorigenesis	and	cell	cycle.	The	precise	mechanisms	
by	which	ZNRD1	is	involved	in	these	processes,	and	
which	of	 these	changes	were	primary	or	secondary	
ones,	remained	to	be	elucidated.
Normal
tissues
ZNRD1
ZNRD1
Gastric
cancer
Multi-drug
resistance
Drugs
fig. 2. The	advances	 in	ZNRD1	 research.	ZNRD1	has	been	
found	to	be	implicated	in	transcription	regulation	of	many	genes	
and	might	play	potential	roles	in	mediating	multidrug	resistance,	
tumorigenesis	and	cell	cycle
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БЕЛОК, сОдЕржащий цинКсвязывающий дОмЕн 
(ZNRD�): мОдуЛятОр мнОжЕствЕннОй рЕзистЕнтнОсти 
К ЛЕКарствЕнным срЕдствам, ОнКОгЕнЕза 
и КЛЕтОчнОгО циКЛа
Ген Z��D�, кодирующий белок с цинксвязывающим доменом, клонирован из HLA‑A локуса. �оказано, ��о ZNRD1 �ри‑     
нимае� у�ас�ие в регуляции �ранскри�ции и, возможно, в целом ряде биологи�еских �роцессов, в �ом �исле множес�венной 
ус�ой�ивос�и к лекарс�венным �ре�ара�ам, онкогенезе и регуляции кле�о�ного цикла. В обзоре обсуждены �оследние 
резуль�а�ы в э�ой облас�и и �риведены данные о роли Z��D� в �роцессах ре�арации ДНК.
Ключевые слова: ZNRD1, рак желудка, кле�о�ный цикл, множес�венная ус�ой�ивос�ь к лекарс�венным �ре�ара�ам.         
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